Catalyst Biosciences, Isu Abxis deal

Catalyst and Isu partnered to develop Catalyst's FIX-NG ( CB 2679d) through Phase I testing to prevent and treat bleeding in hemophilia B patients. The recombinant Factor IX protein is in preclinical testing, with Phase I slated to start in 2015. Isu Abxis will fund and develop FIX-NG through Phase I testing and will receive an undisclosed percentage of potential revenue. Isu Abxis also has an exclusive option to license rights to commercialize FIX-NG in South Korea. ...